Compare TG Therapeutics Inc (TGTX) vs VICI Properties Inc (VICI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs VICI Properties Inc — how do they compare? TG Therapeutics Inc trades at $49.8 (market cap $7.64B), while VICI Properties Inc trades at $26.07 (market cap $28.61B). The key difference: VICI Properties Inc is far larger — about 3.7× TG Therapeutics Inc's market cap, and VICI Properties Inc pays a 6.93% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | VICI | |
|---|---|---|
Market Cap | $7.64B | $28.61B |
Sector | Health | Real Estate |
52-Week High | $59.06 | $33.78 |
52-Week Low | $26.94 | $25.94 |
Enterprise Value | $7.84B | $46.16B |
Dividend Yield | — | 6.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $49.66, up 1.02% on the day, with a bearish technical signal and recent earnings misses despite strong revenue growth. The company reported Q2 2026 revenue of $240 million and raised full-year BRIUMVI guidance to $950 million, but net income was impacted by manufacturing investments. Valuation ratios show a high P/E of 18.22 and EV/EBITDA of 56.26, while profitability metrics like ROE of 100.28% remain robust.
Outlook is mixed: strong product demand and raised revenue targets support growth, but earnings volatility and a bearish technical trend pose risks. Analyst consensus is bullish with an $63.75 price target, though legal investigations and competitive pressures require monitoring for stock investors.
VICI Properties trades at $26.03, down 0.17% on the day, with a bearish technical signal from moving averages but neutral oscillators. The stock shows strong fundamentals with a P/E of 10.07, net income margin of 67.5%, and a recent dividend of $0.45 paid in July 2026. Q2 2026 earnings saw an EPS miss at $0.48 versus $0.713 expected, though revenue beat forecasts, and the company raised its AFFO guidance.
Analyst consensus is strongly bullish with a $29.83 price target and 76.9% buy ratings, highlighting the 6.6% dividend yield and solid cash flow. Key risks include high debt levels, interest expense pressure, and uncertainty from the Caesars acquisition overhang, but the REIT's tangible assets and oligopoly advantages support long-term income appeal.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About VICI Properties Inc
VICI Properties is an S&P 500 experiential real estate investment trust (REIT) that owns one of the largest portfolios of market-leading gaming, hospitality, and entertainment destinations, including Caesars Palace and MGM Grand. It utilizes a long-term, triple-net lease model to provide stable, inflation-protected income, serving as the primary landlord for the 'experience economy' while diversifying into non-gaming sectors like wellness, youth sports, and luxury resorts.
Read more on VICI →
